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ABSTRACT: Patients with Parkinson’s disease (PD) are
very vulnerable to the negative effects of psychological
distress: neuropsychiatric symptoms, such as anxiety and
depression, are highly prevalent in PD; motor symptoms
(such as tremor) typically worsen in stressful situations;
and dopaminergic medication is less effective. Further-
more, animal studies of PD suggest that chronic stress
may accelerate disease progression. Adequate self-
management strategies are therefore essential to reduce
the detrimental effects of chronic stress on PD. Mindful-
ness-based interventions encourage individuals to inde-
pendently self-manage and adapt to the challenges
created by their condition. In PD, emerging clinical evi-
dence suggests that mindfulness-based interventions may
reduce psychological distress and improve clinical symp-
toms, but insight into the underlying mechanisms is
lacking. In this viewpoint, we provide a systematic over-
view of existing mindfulness trials in PD. Furthermore, we
discuss the cerebral mechanisms involved in acute and
chronic stress, and the impact of mindfulness-based
interventions on these networks. In addition, we delin-
eate a hypothetical mechanistic framework of how
chronic stress may increase the susceptibility for neuro-
psychiatric symptoms in PD and may potentially even
influence disease progression. We end with offering rec-
ommendations for future research. © 2020 The Authors.
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Parkinson’s disease (PD) is the fastest growing neuro-
logical disorder in the world: the number of people
with PD has doubled to more than 6 million in the last
two decades. PD is characterized by the motor symp-
toms bradykinesia, rigidity, and tremor, but patients
invariably also have nonmotor symptoms, such as anxi-
ety, depression, cognitive impairment, sleeping prob-
lems, or constipation. The pathophysiological hallmark
of PD is a profound loss of nigrostriatal dopaminergic
neurons and, to a lesser extent, of serotoninergic and
noradrenergic neurons. There is converging clinical evi-
dence that patients with PD are very sensitive to the
effects of psychological stress. First, the prevalence of
stress-related neuropsychiatric symptoms in PD is high:
30% to 40% for depression1 and 25% to 30% for anx-
iety.2 Second, widespread clinical evidence suggests that
stressful episodes worsen certain PD motor symptoms,
such as tremor,3 freezing of gait,4 and dyskinesia.5 Fur-
thermore, we have recently shown in 358 patients with
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PD that coronavirus disease (COVID)-related stress
was associated with increased (self-reported) severity of
not only motor and neuropsychiatric symptoms (anxi-
ety and depression), but also of nonmotor symptoms,
such as pain, constipation, and sleeping difficulties.6
Third, dopaminergic medication can be less effective in
reducing motor symptoms during stress, as has been
shown for tremor.7 The increased sensitivity of patients
with PD to stress may be related to dopaminergic dys-
function of the striatum: dopamine-dependent adapta-
tion (or flexibility) is a requirement for successful
coping that, when deficient, leads to a sense of loss of
control and increased psychological distress.8 In this
viewpoint, we discuss the detrimental effect of chronic
stress on PD and how mindfulness-based interventions
may mitigate this effect, both from a clinical and a
mechanistic standpoint.
In healthy individuals, the physiological stress
response is critical to anticipate real or perceived
threats, to restore homeostatic balance.9 It consists of
the fast adrenomedullary response that triggers (nor)
adrenaline release, resulting in pupil dilation and
increased heart rate, respiration and perfusion of active
tissues, and the slower hypothalamic–pituitary–adrenal
(HPA) axis stimulating cortisol secretion. The HPA sys-
tem is modulated by negative-feedback loops to protect
against prolonged activity. However, chronic stress
leads to dysregulation of this feedback mechanism,
resulting in elevated glucocorticoid levels, and this has
indeed been observed in PD cohorts.10 To reduce the
detrimental effects of chronic stress in PD, adequate
self-management strategies are essential. In recent years,
evidence for the effect of nonpharmacological treat-
ments for PD, such as exercise, has accumulated,11 but
the evidence for stress-alleviating interventions is much
less clear.
Mindfulness-based interventions have at its core the
encouragement of individuals to independently self-
manage and adapt to the challenges created by their
condition. It is the trainable capacity to experience the
present moment, on purpose and without judgment,
while being resilient to experienced joy and sadness.12
The originally Buddhist tradition was used to develop a
structured mindfulness-based stress reduction course
and later mindfulness-based cognitive therapy. The key
difference between these two is that mindfulness-based
cognitive therapy includes some cognitive behavioral
techniques, such as relapse prevention strategies, in
addition to the meditation exercises. Both interventions
consist of an 8-week structure where mediation exer-
cises such as sitting and yoga exercises are alternated
with dialogue and psychoeducation. In several chronic
conditions, such as depression, cancer, chronic pain,
and cardiovascular disease, positive effects of
mindfulness-based interventions have been reported on
stress, anxiety, depression, physical functioning, and
quality of life (QoL).13,14 Mindfulness may have similar
beneficial effects in PD.12 Here, we start by giving a sys-
tematic overview of previous mindfulness trials in PD,
focusing on the effects on nonmotor (depression and
anxiety) and motor symptoms and QoL. Then we dis-
cuss the cerebral networks involved in mediating stress
and how mindfulness may impact on these networks.
Next, we discuss the potential neurobiological mecha-
nisms by which chronic stress may increase susceptibil-
ity for depressive and anxiety disorders and influence
disease progression in PD. We end with offering recom-
mendations for future research.
Clinical Effect of Mindfulness-Based
Interventions
Nine studies tested the effects of a mindfulness-based
intervention on clinical symptoms in PD, and all studies
reported positive results (Table 1). An overview of the
search strategy, study characteristics, and quality
assessment can be found in the Supporting Information.
One study reported only qualitative findings; here we
focused on the remaining eight quantitative studies.
Interestingly, 6/8 trials reported a reduced depression
score after mindfulness-based interventions, and 4/7
studies reported reduced anxiety scores. Motor symp-
toms were assessed in only three studies, of which two
reported significant improvement after a mindfulness-
based intervention. Two of eight studies found signifi-
cant improvement in QoL.
An important issue is whether these findings are clini-
cally relevant. This is the case when a change is larger
than the minimal clinically important difference
(MCID), the smallest difference in score that informed
patients perceive as important. With regard to anxiety
and depression rating scales, MCIDs in PD populations
have only been established for the Beck Depression
Inventory,15 Geriatric Depression Scale (GDS)-30,16
and Hospital Anxiety and Depression Scale (HADS)17
(Supporting Information). From this we can conclude
that the improvement in HADS-D depression score of
2.6 points and in HADS-A anxiety score of 2.4 points
reported by Kwok et al.18 is likely clinically relevant
(HADS-D: MCID = 1.7 points; HADS-A: MCID = 1.8
points), whereas the improvement in GDS-30 depres-
sion of 3.4 points reported by Son et al.19 is not
(MCID = 5.4). For motor symptoms, all trials used
Movement Disorder Society Unified Parkinson’s Dis-
ease Rating Scale Part III (MDS-UPDRS III) scores as
an outcome measure, for which the MCID threshold
was estimated to be 3.25 points.20 Only one of three
studies showed a significant improvement of 13.8
points in the intervention group. For QoL question-
naires, the estimated MCID in patients with PD for the
Parkinson’s Disease Questionnaire (PDQ)-39 is −4.7
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points (improvement) and +4.2 points (worsening),
whereas the MCID for the PDQ-8 is −5.9 and +4.9
points.21 None of the included studies using the PDQ
found a change that exceeded this threshold (Table 1).
Taken together, for many studies it remains unclear
whether the effects were clinically meaningful, either
because the MCID for the outcome measure was
unknown or because the reported effects did not exceed
the MCID. Future studies may take this into account
when choosing the primary outcome measure, using the
MCID as the basis for a power analysis.
The largest randomized controlled trial yet in PD was
performed in Hongkong and compared 71 patients
who received mindfulness yoga training with 67 patients
who received stretching and resistance exercises.18 This
study reported that the mindfulness yoga intervention
significantly improved depression, anxiety, motor
scores, and QoL scores, as compared with the active
control (Table 1). The data also show a remarkable
improvement in the MDS-UPDRS III. Average scores
were reduced from 34.9 (SD 14.9) at study onset to
21.1 after the mindfulness yoga intervention (large
effect size: Cohen’s d = 0.93). It is noteworthy that
these large motor improvements were not accompanied
by clinically relevant improvements in QoL. This MDS-
UPDRS improvement is very large even when compared
with other effective interventions. For example, in
patients with PD starting with 100/25 mg levodopa/car-
bidopa 3x daily, total MDS-UPDRS improved from
28.0 (SD 11.2) to 23.5 points (medium effect size:
Cohen’s d = 0.40).27 Therefore, although the data are
encouraging, these findings must be replicated in future
studies, which should also make clear whether results
from an Asian population can be extrapolated to a
Caucasian population. Taken together, previous studies
suggest that mindfulness-based interventions may
improve depression and anxiety in PD, whereas the evi-
dence for improved motor symptoms and QoL is less
strong.
Cerebral Effects of Stress
and Mindfulness
Acute stress is associated with increased salience net-
work activation, consisting of the amygdala, anterior
cingulate, and insula.28 It also prompts deactivations in
the central executive network, including the























Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control
Advocat (2016) [22] n = 24 n = 33 DASS-D (42) DASS-A (42) PDQ-39 (156)
+1.9a +1.1 +0.3 −0.6 −0.5 −1.5
Birtwell (2017) [23] n = 6 (uncontrolled) DASS-D (42) DASS-A (42) PDQ-39 (156)
−9.0a −7.5a N.I.
Cash (2016) [24] n = 39 (combined:
29 patients with PD
with 10 caregivers)
PHQ-9 (27) GAD-7 (21) PDQ-39 (156)
−1.6a −0.9 −2.4
Dissanayaka (2016) [12] n = 14 (uncontrolled) MDS UPDRS-III (76) HAM-D (52) GAI (20) PDQ-39 (156)
−0.8 −0.8a −1.9a −2.8
Kwok (2019) [23] n = 71 n = 67 MDS UPDRS-III (76)c HADS-D (21)c HADS-A (21)c PDQ-8 (32)c
−13.8a −9.1a −2.6 −0.3 −2.4 −0.4 −2.2 +0.5
Pickut (2015) [25] n = 14 n = 13 MDS UPDRS-III (76)c BDI PDQ-pain (12)
−5.5a +1.1 N.I. N.I. +0.8a −0.7
Rodgers (2019) [26] n = 15 n = 12 DASS-D (42)c DASS-A (42)a PDQ-39 (156)a
−0.8 a +0.4 −0.7 −1.3 −1.8 −3.0
Son (2018) [24] n = 33 n = 30 GDS (30)b STAI (160)b PDQL (185)b
−3.4 −1.0 −6.5 +9.4 +17.4 −8.6
Absolute changes between baseline and postintervention for measures relating to motor symptoms, depression, anxiety, and quality of life are listed. Values in
parentheses are the maximum score per measure. Characteristics of studies and used measures can be found in the Supporting Information. Boldface
indicates improvement; italics indicates worsening at postintervention.
aChange (P < 0.05) between T1 (baseline) and T2 (postintervention).
bDifference (P < 0.05) between groups (in controlled studies) at T2 (postintervention).
c2×2 interactions between time (preintervention and postintervention) and group (intervention and control).
Abbreviations: MDS UPDRS-III, Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III; BDI, Beck Depression Inventory; N.I., not indicated;
DASS, Depression Anxiety Stress Scale (A = anxiety sub-scale, D = depression sub-scale); GAI, geriatric anxiety inventory; GAD, generalized anxiety disorder;
GDS, geriatric depression scale; HADS, hospital anxiety and depression scale (A = anxiety sub-scale, D = depression sub-scale); HAM, Hamilton depression
rating scale; PDQ, Parkinson’s disease questionnaire; PDQL, Parkinson’s disease quality of life; PHQ, patient health questionnaire; STAI, state-trait anxiety
inventory.
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dorsolateral prefrontal cortex, posterior parietal cortex,
precentral sulcus, and frontal eye fields. Chronic stress
leads to neuroplastic changes in key nodes of these net-
works: growth of amygdala and orbitofrontal cortex,
but shrinkage of the hippocampus and medial prefron-
tal cortex (Fig. 1A).29 After a mindfulness-based inter-
vention, reduced stress correlated with gray matter
density decrease in the amygdala but increase in the
hippocampus. In addition, mindfulness-based interven-
tion studies consistently showed increased activity,30 as
well as structural changes,31 in the insula, anterior and
posterior cingulate cortex, striatum, and the medial and
dorsolateral prefrontal cortex (Fig. 1B). All of these
regions have important roles in attentional control,
emotional regulation, and self-awareness, and they
largely overlap with regions where activity changes dur-
ing acute stress. We acknowledge that many other brain
areas are likely also involved in mindfulness practice,
but this requires more research. Only one trial investi-
gated (structural) brain changes after a mindfulness-
based intervention in patients with PD.32 The interven-
tion group showed increased gray matter density in the
hippocampus, amygdala, caudate nucleus, left thala-
mus, temporoparietal junction, cuneus, left occipital
lobe, and left parahippocampal gyrus. The usual care
group showed decreased gray matter density in the
cerebellum.
Cerebral Effects of Chronic
Stress in PD
As outlined earlier, chronic stress influences the brain
both at the systems level (large-scale brain circuits) and
at the molecular level (Fig. 2). Through these changes,
chronic stress may affect PD brains by increasing the
susceptibility to depressive and anxiety disorders, while
also potentially impacting the already injured dopami-
nergic nigrostriatal system in patients with PD. Although
this remains highly speculative at this stage, the follow-
ing mechanisms may contribute to these effects.
First, high levels of glucocorticoids that result from
chronic stress decrease the expression of brain-derived
neurotrophic factor, which facilitates stress-induced
FIG. 1. Brain network activity related to stress and mindfulness. (A) Brain regions are activated (blue) or deactivated (orange) during acute stress,28
resulting in neuroplastic structural changes in core regions after chronic stress.29 (B) Brain regions for which altered activation,30 as well as structural
brain changes,31 have repeatedly been demonstrated in mindfulness practitioners. Blue regions consistently show activation during mindfulness-related
tasks or resting state, whereas orange regions were found to be deactivated. [Color figure can be viewed at wileyonlinelibrary.com]
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remodeling of the hippocampus, amygdala, and pre-
frontal cortex.33 Several studies observed an increase in
brain-derived neurotrophic factor plasma level after
mindfulness or meditation interventions,39 suggesting
that mindfulness-based interventions might counteract
this stress-induced remodeling. This stress-induced atro-
phy in the hippocampus and prefrontal cortex and
growth in the amygdala likely contribute to impaired
cognitive function and emotion regulation, increasing
the risk for development of depressive and anxiety dis-
orders.34 Because of the inhibitory control of the hippo-
campus over the HPA axis,40 hippocampal atrophy
also results in disinhibition of the HPA axis, causing a
positive feedforward cascade that further increases glu-
cocorticoid levels,35 which is another potential vicious
circle. In a similar way, noradrenaline release during
acute stress may influence processing in specific brain
regions. For example, the noradrenaline system excites
the thalamus during a cognitively demanding task,
resulting in increased tremor power.41 Whether similar
mechanisms apply during chronic stress is unclear.
Second, chronic stress might aggravate the progres-
sion of nigrostriatal cell loss in PD, accelerating dis-
ease progression. Findings in rodent models of PD
have provided some evidence in that direction: chronic
stress exacerbated dopaminergic and noradrenergic
neuronal loss,36,42 and injection of corticosterone
(which is elevated in chronic stress) increased the
severity of cerebral alpha-synucleopathy.43 This might
be driven by neuroinflammation: stress hormones
(such as cortisol) affect major immune functions by
increasing microglia activation,36 although inflamma-
tion can, of course, also be triggered by other factors.
Interestingly, in subjects with mild cognitive impair-
ment, mindfulness reduced levels of inflammatory bio-
marker C-reactive protein (CRP).44 In PD, a meta-
analysis showed increased CRP levels, but it is unclear
whether this is associated with stress.45 Furthermore,
the increased energy demands needed to respond to
chronic stress are associated with increased production
of reactive oxygen species, resulting in oxidative dam-
age in several areas, including cortical regions, hippo-
campus and striatum.37 These molecular changes may
contribute to degeneration of nigrostriatal dopaminer-
gic neurons.38 In PD, this could result in a vicious cir-
cle: dopaminergic dysfunction of the striatum increases
the stress sensitivity of affected individuals (because of
impaired coping and reduced behavioral flexibility),
while resulting psychological distress could negatively
impact nigrostriatal dysfunction.8 Additional research
may test this hypothesis.
Another way in which stress might influence PD dis-
ease progression is by depleting compensatory mecha-
nisms. In PD, clinical symptoms usually become
apparent when >50% of dopaminergic cells are lost.
This suggests that compensatory mechanisms must take
place in the early phase of PD to prevent overt clinical
symptoms. These compensatory mechanisms are
thought to take place both in the striatal dopamine sys-
tem and at the level of large-scale brain networks.46
Under stressful conditions, the residual dopaminergic
function is compromised, and attentional resources are
depleted, in a similar way as dual tasking does.47 This
may “unmask” clinical symptoms that were not seen
before or increase the severity of already manifest
symptoms.
FIG. 2. A pathophysiological model of chronic stress in Parkinson’s disease (PD). This figure provides a hypothetical (and simplified) framework of how
chronic stress in patients with PD may lead to higher susceptibility for depressive and anxiety disorders on the one hand, and to a more rapid progres-
sion of the disease on the other hand. Upper part: the high levels of glucocorticoids that result from chronic stress decrease the expression of brain-
derived neurotrophic factor (BDNF), which induces atrophy in the hippocampus and prefrontal cortex and growth in the amygdala.33 This increases the
risk for development of depressive and anxiety disorders.34 Hippocampal atrophy also disinhibits the hypothalamic–pituitary–adrenal (HPA) axis, further
increasing glucocorticoid levels.35 Lower part: elevated glucocorticoid levels also increase neuroinflammation36 and production of reactive oxygen spe-
cies (ROS).37 These molecular changes may contribute to degeneration of nigrostriatal dopaminergic neurons.38
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Recommendations for Future Studies
Future trials should be adequately powered to dem-
onstrate a clinically meaningful difference between a
mindfulness and control intervention (based on
MCIDs). The optimal control intervention should have
a similar duration and amount of personal contact as
mindfulness and should not differ in degree of physical
exercise.48 When investigating the effect of mindfulness
on disease progression, it is possible that interventions
longer than 8 weeks are needed (eg, 18 months in the
Age-Well study in elderly adults49). Promising outcome
measures include (self-reported) anxiety and depression
(Table 1), and it might be considered to test the merits
of mindfulness in a sample of patients with PD scoring
high on these symptoms.50 It would also be informative
to assess effects on other nonmotor symptoms, such as
pain, sleeping problems, and digestive issues. Any
effects on motor symptoms are currently less clear, and
these may be better investigated using wearable devices
to identify even subtle improvements (eg, to detect
effects on stress-sensitive symptoms such as tremor) or
using functional outcome measures. Specifically, such
functional measures could include brain imaging (mag-
netic resonance imaging), activity of the HPA axis (eg,
hair cortisol10), or inflammatory markers (eg, CRP45),
and these may help to better understand the underlying
working mechanisms. Follow-up should ideally be
6 months or longer, because the effects of a
mindfulness-based intervention may consolidate with
longer follow-up.14
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